fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy .
modern insulin analogues are a convenient new approach or tool to glycaemic control , associated with low number of hypoglycaemia and favourable weight change .
a1chieve , a multinational , 24-week , non - interventional study , assessed the safety and effectiveness of insulin analogues in people with t2 dm ( n = 66,726 ) in routine clinical care .
this short communication presents the results for patients enrolled in biphasic insulin aspart sub group from libya .
please refer to editorial titled : the a1chieve study : mapping the ibn battuta trail .
the study was started with an aim to collect data on all the insulin analogue viz insulin detemir , biphasic insulin aspart and insulin aspart . however , due to ongoing revolution , the complete data could not be collected . here
the majority of patients ( 189 ) were started on or were switched to biphasic insulin aspart .
other groups were insulin detemir ( n = 58 ) , basal + insulin aspart ( n = 44 ) and other insulin combinations ( n = 25 ) . being the biggest treatment group , this communication describes the results for patients treated with insulin therapy before and then switched to biphasic insulin aspart .
overall demographic data 179 patients started on biphasic insulin aspart  ogld , and all the patients were on insulin therapy prior to the study .
after 24 weeks of switching to biphasic insulin aspart , hypoglycaemic events reduced from 7.2 events / patient - year to 3.7 events / patient - year [ tables 2 and 3 ] . all parameters of glycaemic control improved from baseline to study end [ table 4 ] . overall efficacy data
179 patients started on biphasic insulin aspart  ogld , and all the patients were on insulin therapy prior to the study .
after 24 weeks of switching to biphasic insulin aspart , hypoglycaemic events reduced from 7.2 events / patient - year to 3.7 events / patient - year [ tables 2 and 3 ] .
all parameters of glycaemic control improved from baseline to study end [ table 4 ] .
our study reports improved glycaemic control following 24 weeks of treatment with biphasic insulin aspart with or without ogld .
hypoglycemic events decreased from baseline and sadrs did not occur in any of the study patients .
though the findings are limited by number of patients , still the trend indicates that biphasic insulin aspart can be considered effective and possess a safe profile for treating type 2 diabetes in libya .
 background : the a1chieve , a multicentric ( 28 countries ) , 24-week , non - interventional study evaluated the safety and effectiveness of insulin detemir , biphasic insulin aspart and insulin aspart in people with t2 dm ( n = 66,726 ) in routine clinical care across four continents.materials and methods : data was collected at baseline , at 12 weeks and at 24 weeks . this short communication presents the results for patients enrolled in biphasic insulin aspart sub group from libya.results:a total of 179 patients were enrolled in the biphasic insulin aspart subgroup . 
 all the patients were prior insulin users . at baseline 
 glycaemic control was poor ( mean hba1c : 9.3% ) . 
 after 24 weeks of treatment there was an improvement in hba1c ( 0.9% ) . 
 hypoglycaemic events reduced from 7.2 events / patient - year to 3.7 events / patient - year in 24 weeks . 
 sadrs did not occur in any of the study patients.conclusion:starting or switching to biphasic insulin aspart was associated with improvement in glycaemic control with a low rate of hypoglycaemia . 
I
M
R
Safety data
Efficacy data
C